Acquisitions, Clinical Trial Results and Stock Price Movements - Research Report on ViroPharma, Pfizer, Alkermes, Tenet, and

  Acquisitions, Clinical Trial Results and Stock Price Movements - Research
          Report on ViroPharma, Pfizer, Alkermes, Tenet, and ResMed

PR Newswire

NEW YORK, November 14, 2013

NEW YORK, November 14, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting ViroPharma
Inc. (NASDAQ: VPHM), Pfizer Inc. (NYSE: PFE), Alkermes plc (NASDAQ: ALKS),
Tenet Healthcare Corp. (NYSE: THC), and ResMed Inc. (NYSE: RMD). Today's
readers may access these reports free of charge - including full price
targets, industry analysis and analyst ratings - via the links below.

ViroPharma Inc. Research Report

On November 11, 2013, ViroPharma Inc. (ViroPharma) and Shire plc (Shire)
announced that the Board of Directors of both Companies have unanimously
approved a merger agreement under which Shire will acquire all outstanding
shares of ViroPharma for $50 per share in cash, for a total consideration of
approximately $4.2 billion. According to ViroPharma, the $50 per share price
in the transaction represents a 64% premium to ViroPharma's unaffected share
price of $30.47 on September 12, 2013. Vincent J. Milano, ViroPharma CEO,
said, "By joining with Shire, ViroPharma will become part of a larger, more
diverse biopharmaceutical company and will benefit from Shire's innovation,
scale and global reach. We will have access to resources to expand product
distribution, giving us a platform to provide our crucial therapies, such as
CINRYZE, to more patients than ever before." Shire CEO, Flemming Ornskov MD
commented, "The acquisition of ViroPharma will immediately benefit Shire and
is entirely consistent with our clear strategic objective of strengthening our
rare disease portfolio." ViroPharma informed that closing of the transaction
is subject to customary conditions, including the tender of a majority of the
outstanding ViroPharma shares and the receipt of regulatory clearances. The
Companies stated that pending anti-trust authority clearances, it expect the
transaction to close in Q4 2013, Q1 2014, or as soon as possible thereafter.
The Full Research Report on ViroPharma Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:

[http://www.analystscorner.com/r/full_research_report/c730_VPHM]

Pfizer Inc. Research Report

On November 8, 2013, Pfizer Inc. (Pfizer) announced top-line results from a
Phase 3B/4 study of RAPAMUNE (sirolimus) evaluating kidney transplant patients
who transitioned from tacrolimus-based therapy (TAC) to RAPAMUNE 3 to 5 months
after transplant. According to Pfizer, the primary endpoint of the study was
not achieved as there was not a statistically significant difference in renal
function improvement between patients who continued receiving TAC and those
who switched to RAPAMUNE. Pfizer added that for patients who were switched to
RAPAMUNE, 33.7% of patients achieved the primary endpoint of a ≥ 5
ml/min/1.73m2 renal function improvement based on glomerular filtration rate
(GFR) from randomization to 24 months post-transplantation, and 42.3% of
patients continuing to take TAC achieved the primary endpoint (p=0.239). The
Company informed that RAPAMUNE is indicated for the prevention of organ
transplant rejection in kidney transplant patients aged 13 years and older in
the US. Pfizer further stated that the study was an open-label, randomized,
comparative, multi-center, multi-national study conducted in Europe, Latin
America, North America, and the Pacific Region. Pfizer also informed that
there were 256 subjects in the study randomized at 3 to 5 months after
transplant, with two subjects not receiving any medication. The Full Research
Report on Pfizer Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/d702_PFE]

Alkermes plc Research Report

On November 11, 2013, Alkermes plc's stock rose 1.77%, ending the day at
$36.76. Over the previous three trading sessions, shares of Alkermes gained
4.58%, compared to the Nasdaq Composite which declined 0.31% and the Dow Jones
Industrial Average which gained 0.23% during the same period. The Full
Research Report on Alkermes plc - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/e2f3_ALKS]

Tenet Healthcare Corp. Research Report

On November 11, 2013, Tenet Healthcare Corp.'s stock (Tenet) declined 0.52%,
ending the day at $42.11. Over the previous three trading sessions, shares of
Tenet declined 3.79% compared to the S&P 500 which gained 0.08% and the Dow
Jones Industrial Average which gained 0.23% during the same period. The Full
Research Report on Tenet Healthcare Corp. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at:

[http://www.analystscorner.com/r/full_research_report/1d25_THC]

ResMed Inc. Research Report

On November 11, 2013, ResMed Inc.'s stock (ResMed) gained 0.26%, ending the
day at $50.74. Over the previous three trading sessions, shares of ResMed
gained 1.72% compared to the S&P 500 which gained 0.08% and the Dow Jones
Industrial Average which gained 0.23% during the same period. The Full
Research Report on ResMed Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/bd44_RMD]

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we
    are only human and are prone to making mistakes. If you notice any errors
    or omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Namrata Maheshwari,
CFA, has only reviewed the information provided by Equity News Network in this
article or report according to the Procedures outlined by Equity News Network.
Equity News Network is not entitled to veto or interfere in the application of
such procedures by the outsourced provider to the articles, documents or
reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

http://www.analystscorner.com/

SOURCE Analysts' Corner

Contact: CONTACT PERSON: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North
America)
 
Press spacebar to pause and continue. Press esc to stop.